Rik J. Verheijden

Statistics

Publications

Citations

468

H-Index

Active since

2020

Affiliations

University Medical Center Utrecht(Current)

Utrecht University

Maastricht University Medical Centre

Erasmus University Rotterdam

Radboud University Medical Center

Rik J. Verheijden is an author at University Medical Center Utrecht specializing in oncology, immune checkpoint inhibitors, and checkpoint inhibitor therapy.

ORCID

Publications per year

2020–2025

Publications

Association of Immune-Related Adverse Event Management With Survival in Patients With Advanced Melanoma

Olivier J. van Not, Rik J. Verheijden, Alfonsus Johannes Maria van den Eertwegh et al. · JAMA Oncology · 2022 · 106 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Corticosteroids for Immune-Related Adverse Events and Checkpoint Inhibitor Efficacy: Analysis of Six Clinical Trials

Rik J. Verheijden, Jolien S. de Groot, Babs O. Fabriek et al. · Journal of Clinical Oncology · 2024 · 93 citations · Full text

Life Sciences, Immunology, Oncology +17

Corticosteroids and other immunosuppressants for immune-related adverse events and checkpoint inhibitor effectiveness in melanoma

Rik J. Verheijden, F.H. Burgers, Josephine C Janssen et al. · European Journal of Cancer · 2024 · 54 citations · Full text

Pharmacy, Immunology, Oncology +16

Frailty and checkpoint inhibitor toxicity in older patients with melanoma

Cheryl P. Bruijnen, José J. Koldenhof, Rik J. Verheijden et al. · Cancer · 2022 · 42 citations · Full text

Medicine, Geriatric Medicine, Oncology +17

Physical activity and checkpoint inhibition: association with toxicity and survival

Rik J. Verheijden, Anna Cabané Ballester, Karel C. Smit et al. · JNCI Journal of the National Cancer Institute · 2023 · 27 citations · Full text

Life Sciences, Immunology, Oncology +17

1–5 of 14